CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy
Open Access
- 16 November 2022
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (46) , eabo7621
Abstract
Tumors exploit numerous immune checkpoints, including those deployed by myeloid cells to curtail antitumor immunity. Here, we show that the C-type lectin receptor CLEC-1 expressed by myeloid cells senses dead cells killed by programmed necrosis. Moreover, we identified Tripartite Motif Containing 21 (TRIM21) as an endogenous ligand overexpressed in various cancers. We observed that the combination of CLEC-1 blockade with chemotherapy prolonged mouse survival in tumor models. Loss of CLEC-1 reduced the accumulation of immunosuppressive myeloid cells in tumors and invigorated the activation state of dendritic cells (DCs), thereby increasing T cell responses. Mechanistically, we found that the absence of CLEC-1 increased the cross-presentation of dead cell–associated antigens by conventional type-1 DCs. We identified antihuman CLEC-1 antagonist antibodies able to enhance antitumor immunity in CLEC-1 humanized mice. Together, our results demonstrate that CLEC-1 acts as an immune checkpoint in myeloid cells and support CLEC-1 as a novel target for cancer immunotherapy.Keywords
This publication has 53 references indexed in Scilit:
- C-Type Lectin-Like Receptors of the Dectin-1 Cluster: Ligands and Signaling PathwaysInternational Reviews of Immunology, 2013
- Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus ErythematosusInternational Journal of Rheumatology, 2012
- The Human C‐Type Lectin‐Like Receptor CLEC‐1 is Upregulated by TGF‐β and Primarily Localized in the Endoplasmic Membrane CompartmentScandinavian Journal of Immunology, 2011
- Antigen Localization Controls T Cell-Mediated Tumor ImmunityThe Journal of Immunology, 2011
- The C-Type Lectin-Like Receptor CLEC-1, Expressed by Myeloid Cells and Endothelial Cells, Is Up-Regulated by Immunoregulatory Mediators and Moderates T Cell ActivationThe Journal of Immunology, 2009
- DNA/Amphiphilic Block Copolymer Nanospheres Promote Low-dose DNA VaccinationMolecular Therapy, 2009
- Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23–Th17 pathwayJournal of Experimental Medicine, 2009
- Gene Disruption Study Reveals a Nonredundant Role for TRIM21/Ro52 in NF-κB-Dependent Cytokine Expression in FibroblastsThe Journal of Immunology, 2009
- Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell ImmunityScience, 2008
- Antibody-enhanced cross-presentation of self antigen breaks T cell toleranceJournal of Clinical Investigation, 2007